Chemotherapy-induced nausea and vomiting in Portugal: incidence versus healthcare provider estimations and effect on quality of life
José Dinis(Instituto Português de Oncologia Francisco Gentil), Thomas Burke(Merck & Co., Inc., Rahway, NJ, USA (United States)), A.L.N. Moreira(Instituto de Engenharia de Sistemas e Computadores Investigação e Desenvolvimento), João Filipe Raposo(Universidade Nova de Lisboa), Larry Ma, Tami Wisniewski
Cited by 3
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
|New England Journal of Medicine|2011|1.1k
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
|Journal of Clinical Oncology|2011|221
Review of methods for detecting glycemic disorders
|Diabetes Research and Clinical Practice|2020|193